Cancer name Non Small Cell Lung Cancer
Cancer Type NSCLC
Immunotherapy type Immune Checkpoint Therapy
Treatment M7824(Bintrafusp alfa)
Drugstatus Investigational
Drugbank ID DB15387
Checkpoints PD-L1
Signature Type Protein
Signature mesenchymal fibronectin
Official Symbol FN1
Mode of action PROT_D_DOWN
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description Similarly, in cells that had already undergone 3 d of TGF-b1-induced EMT, simultaneous treatment with TGF-b1 and M7824 for a subsequent 3 d (termed TGF-b1reversion) was found to decrease mesenchymal fibronectin and vimentin in both cell lines, and restore E-cadherin expression in A549 cells.
PMID 29123964
Title A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells